Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Burkitt Lymphoma 27Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Myelodysplastic Syndromes 20Leukemia, Myeloid, Chronic-Phase 20Lymphoma, Follicular 19Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia, Myeloid, Accelerated Phase 17Multiple Myeloma 16Lymphoma, Large-Cell, Immunoblastic 15Blast Crisis 15Myeloproliferative Disorders 14Leukemia, Myeloid, Acute 14Dendritic Cell Sarcoma, Interdigitating 14Recurrence 13Lymphoma, Mantle-Cell 13Lymphoma, B-Cell, Marginal Zone 13Graft vs Host Disease 13Leukemia, Myelomonocytic, Chronic 12Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 12Hodgkin Disease 11Congenital Abnormalities 11Neoplasms, Plasma Cell 10Myelodysplastic-Myeloproliferative Diseases 10Anemia, Refractory, with Excess of Blasts 9Primary Myelofibrosis 8Lymphoma, Large-Cell, Anaplastic 8

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 26Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Methylprednisolone × Clear all
NCT02962284 2021-11-19

One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSAâ„¢

Sun Pharmaceutical Industries Limited

Phase 2 Completed
20 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00541281 2009-10-27

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Completed
150 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡